[en] Arterial hypertension is a significant risk factor for cardiovascular disease, proportional to the blood pressure level. Treating hypertension reduces the risk. Until recently, beta-blockers were considered as a first line class for hypertension management. The British Hypertension Society has recently pronounced that using beta-blockers as first line antihypertensive therapy is no good choice since these agents are less protective than other antihypertensive classes against cardiovascular disorders and diabetes mellitus, especially when used in association with diuretics. [fr] L’hypertension artérielle expose à un risque cardio-vasculaire proportionnel aux valeurs de pression artérielle. Le traitement de l’hypertension artérielle réduit ce risque. Jusqu’il y a peu, les médicaments de première ligne comprenaient entre autres, les bêta-bloquants. Suite à diverses métaanalyses, la Société Britannique d’Hypertension a récemment mis les bêtabloquants au banc des accusés, responsables d’une moins bonne protection cardio-vasculaire que les autres agents antihypertenseurs et source de diabète, surtout en association
avec les diurétiques.
Disciplines :
Urology & nephrology
Author, co-author :
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Saint-Remy, Annie ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Language :
French
Title :
Les bêtabloquants sont-ils encore des medicaments de premier choix pour le traitement de l'hypertension arterielle non compliquee?
Alternative titles :
[en] Evidence for Avoiding the Use of Beta-Blockers as First Line Therapy in Hypertension
Publication date :
2007
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Krzesinski J-M. - Actualisation de la prise en charge de l'hypertension artérielle. Rev Med Liège, 1999, 54, 683-687.
Guidelines Committee. - 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21, 1011-1053.
Blood pressure lowering treatment trialists' collaboration. - Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362, 1527-1535.
Traitement initial de l'hypertension : état de la question. Folia Pharmacotherapeutica, 2004, 31, 28-32.
http://www.nice.org.uk/CG034NICEguideline. - Les nouveaux antihypertenseurs sont plus intéressants en terme de prévention du risque cardio-vasculaire que les «anciens» comprenant bêta-bloquants et diurétiques.
Khan N, McAlister F. - Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ, 2006, 174, 1737-1742.
Dahlöf B, Sever P, Poulter N et al. - Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) : a multicentre randomised controlled trial. Lancet, 2005, 366, 895-906.
Bradley HA, Wiysonge CS, Volmink JA, et al. - How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens, 2006, 24, 2131-2141.
Carlberg B, Samuelsson O, Lindholm LH. - Atenolol in hypertension : is it a wise choice? Lancet, 2004, 364, 1684-1689.
Wysonge CS, Bradley H, Mayosi B et al. - Beta-blockers for hypertension. Cochrane Database of Systematic Reviews, 2007, 1, CD002003.
Freemantle N, Cleland J, Young P, ET AL. - Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 1999, 318, 1730-1737.
Dahlöf B, Devereux R, Kjeldsen S, et al. - Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
Lindholm LH, Carlberg B, Samuelsson O. - Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 2005, 366, 1545-1553.
Hasford J, Mimram A, Simons W. - A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens, 2002, 16, 569-575.
Staessen J.A., Brikenhäger W.H. - Evidence that new antihypertensives are superior to older drugs. Lancet, 2005, 366, 869-871.
O'Rourke M for The CAFE investigators, for the Anglo-Scandinavian Cardiac Outcomes (ASCOT) investigators. - Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation, 2006, 113, 1213-1225.
Mancia G, Grassi G, Zanchetti A. - New-onset diabetes and hypertensive drugs. J Hypertens, 2006, 24, 3-10.
Stump G, Hamilton M, Sowers J. - Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc, 2006, 81, 796-806.
